AstraZeneca’s asthma drug nears approval for sinus inflammation

AstraZeneca and Amgen have jointly developed the drug Tezspire, which has shown highly promising results in Phase III studies for patients suffering from chronic inflammation of the nose and sinuses, as well as nasal polyps.

The European Medicines Agency’s scientific committee, CHMP, has now evaluated the drug and recommends its approval in the EU.